RA Capital Management L.P. Makes New $761,000 Investment in Scholar Rock Holding Co. (NASDAQ:SRRK)

RA Capital Management L.P. acquired a new stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,616 shares of the company's stock, valued at approximately $761,000.

Several other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares in the last quarter. Global Retirement Partners LLC raised its holdings in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. Amalgamated Bank boosted its position in shares of Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares during the period. Finally, KBC Group NV purchased a new stake in Scholar Rock in the 4th quarter worth $131,000. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Price Performance

SRRK stock traded up $0.15 during midday trading on Friday, reaching $32.91. The stock had a trading volume of 1,339,190 shares, compared to its average volume of 1,260,274. The company's fifty day simple moving average is $32.26 and its 200 day simple moving average is $35.83. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -14.00 and a beta of 0.56. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98.

Insiders Place Their Bets

In related news, insider Tracey Sacco sold 6,500 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the transaction, the insider now directly owns 71,750 shares of the company's stock, valued at $2,373,490. The trade was a 8.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares of the company's stock, valued at $4,154,541.60. This trade represents a 38.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 255,231 shares of company stock valued at $9,220,236 in the last ninety days. 13.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Scholar Rock has an average rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.